Preventing Pancreatitis After ERCP: Drugs Alone, or with Stents?

Randomized trial data suggest that stent use can be minimized in this setting.

The use of rectal indomethacin as prophylaxis against post–endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is now widespread. Pancreatic duct stents, when used for PEP prophylaxis, have been shown to have similar benefits to indomethacin. In the current randomized, controlled, double-blind, noninferiority study, researchers compared the effectiveness of a pharmacologic regimen alone or combined with pancreatic stents for the prevention of PEP in high-risk patients.

More than 400 patients were randomized to receive pharmacologic prophylaxis (100 mg indomethacin given rectally, 5 mg sublingual isosorbide dinitrate, and hydration with Ringer's lactate) plus insertion of a short, 5-Fr pancreatic duct stent, or pharmacolo…

Reviewing Author

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Preventing Pancreatitis After ERCP: Drugs Alone, or with Stents?

Topics

Reviewing Author